Tokyo Tape
Sign in
← PeptiDream

Half-year report · HY

4587.TEDINET S100YVU6
Period2026-01-01 → 2026-06-30
Filed2026-08-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥9.2bn2026-01-01 → 2026-06-30Cons.Revenue IFRS
Revenue¥18.5bn2025-01-01 → 2025-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥8.5bn2025-01-01 → 2025-06-30Cons.Revenue IFRS
Operating income−¥2.5bn2026-01-01 → 2026-06-30Cons.Operating profit loss IFRS
Operating income−¥2.6bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Profit before tax−¥2.7bn2026-01-01 → 2026-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥5.3bn2025-01-01 → 2025-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥2.9bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Net income (owners)−¥2.0bn2026-01-01 → 2026-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥3.7bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥2.0bn2026-01-01 → 2026-06-30Cons.Profit loss IFRS
Net income−¥3.7bn2025-01-01 → 2025-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Total assets¥72.2bnat 2026-06-30Cons.Assets IFRS
Total assets¥77.0bnat 2025-12-31Cons.Assets IFRS
Total assets¥78.5bnat 2025-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥23.7bnat 2026-06-30Cons.Liabilities IFRS
Total liabilities¥25.5bnat 2025-12-31Cons.Liabilities IFRS
Net assets / equity¥48.6bnat 2026-06-30Cons.Equity IFRS
Net assets / equity¥51.5bnat 2025-12-31Cons.Equity IFRS
Net assets / equity¥53.7bnat 2025-06-30Cons.Equity IFRS
Net assets / equity¥56.8bnat 2024-12-31vCons.Equity IFRS
Equity (owners)¥48.6bnat 2026-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥51.5bnat 2025-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥53.7bnat 2025-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥23.6bnat 2026-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥28.7bnat 2025-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥33.3bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥48.1bnat 2024-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.8bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥13.3bn2025-01-01 → 2025-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥11.0bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥614m2026-01-01 → 2026-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥2.1bn2025-01-01 → 2025-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.3bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.7bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥4.1bn2025-01-01 → 2025-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥2.5bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-15.512026-01-01 → 2026-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-28.992025-01-01 → 2025-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-16.42025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-15.512026-01-01 → 2026-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-28.992025-01-01 → 2025-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-16.42025-01-01 → 2025-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio67.2%at 2026-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.9%at 2025-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.3%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2026-01-01 → 2026-06-30−¥512m
Reconciling Itemsreconcilingrevenue intersegment2026-01-01 → 2026-06-30−¥512m
Drug Discovery And Development Businessreportable segmentrevenue2026-01-01 → 2026-06-30¥1.2bn
Drug Discovery And Development Businessreportable segmentrevenue external2026-01-01 → 2026-06-30¥1.2bn
Drug Discovery And Development Businessreportable segmentsegment profit2026-01-01 → 2026-06-30−¥2.7bn
Radiopharmaceuticals Businessreportable segmentrevenue2026-01-01 → 2026-06-30¥8.5bn
Radiopharmaceuticals Businessreportable segmentrevenue external2026-01-01 → 2026-06-30¥8.0bn
Radiopharmaceuticals Businessreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥512m
Radiopharmaceuticals Businessreportable segmentsegment profit2026-01-01 → 2026-06-30¥242m
—segment totalrevenue2026-01-01 → 2026-06-30¥9.7bn
—segment totalrevenue external2026-01-01 → 2026-06-30¥9.2bn
—segment totalrevenue intersegment2026-01-01 → 2026-06-30¥512m
—segment totalsegment profit2026-01-01 → 2026-06-30−¥2.5bn
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥453m
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥453m
Drug Discovery And Development Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥761m
Drug Discovery And Development Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥761m
Drug Discovery And Development Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥3.0bn
Radiopharmaceuticals Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥8.2bn
Radiopharmaceuticals Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥7.8bn
Radiopharmaceuticals Businessreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥453m
Radiopharmaceuticals Businessreportable segmentsegment profit2025-01-01 → 2025-06-30¥436m
—segment totalrevenue2025-01-01 → 2025-06-30¥9.0bn
—segment totalrevenue external2025-01-01 → 2025-06-30¥8.5bn
—segment totalrevenue intersegment2025-01-01 → 2025-06-30¥453m
—segment totalsegment profit2025-01-01 → 2025-06-30−¥2.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 571
ItemContextValueUnit
Profit loss attributable to owners of parent IFRSPrior1InterimDuration-2122490000JPY
Profit loss attributable to owners of parent IFRSInterimDuration-1999424000JPY
Basic earnings loss per share IFRSPrior1InterimDuration-16.40
Basic earnings loss per share IFRSInterimDuration-15.51
Diluted earnings loss per share IFRSPrior1InterimDuration-16.40
Diluted earnings loss per share IFRSInterimDuration-15.51
Profit loss IFRSPrior1InterimDuration-2122490000JPY
Profit loss IFRSInterimDuration-1999424000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1InterimDuration－JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSInterimDuration-6268000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1InterimDuration－JPY
Total of items that will not be reclassified to profit or loss oci IFRSInterimDuration-6268000JPY
Other comprehensive income IFRSPrior1InterimDuration－JPY
Other comprehensive income IFRSInterimDuration-6268000JPY
Comprehensive income IFRSPrior1InterimDuration-2122490000JPY
Comprehensive income IFRSInterimDuration-2005693000JPY
Comprehensive income attributable to owners of parent IFRSPrior1InterimDuration-2122490000JPY
Comprehensive income attributable to owners of parent IFRSInterimDuration-2005693000JPY
Equity IFRSPrior2YearInstant_ShareCapitalIFRSMember3956738000JPY
Equity IFRSPrior2YearInstant_CapitalSurplusIFRSMember4736195000JPY
Equity IFRSPrior2YearInstant_TreasurySharesIFRSMember-1075148000JPY
Equity IFRSPrior2YearInstant_RetainedEarningsIFRSMember49393469000JPY
Equity IFRSPrior2YearInstant_OtherComponentsOfEquityIFRSMember-248956000JPY
Equity IFRSPrior2YearInstant_EquityAttributableToOwnersOfParentIFRSMember56762298000JPY
Equity IFRSPrior2YearInstant56762298000JPY
Profit loss IFRSPrior1InterimDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSPrior1InterimDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSPrior1InterimDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSPrior1InterimDuration_RetainedEarningsIFRSMember-2122490000JPY
Profit loss IFRSPrior1InterimDuration_OtherComponentsOfEquityIFRSMember－JPY
Profit loss IFRSPrior1InterimDuration_EquityAttributableToOwnersOfParentIFRSMember-2122490000JPY
Profit loss IFRSPrior1InterimDuration-2122490000JPY
Other comprehensive income IFRSPrior1InterimDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSPrior1InterimDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSPrior1InterimDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSPrior1InterimDuration_RetainedEarningsIFRSMember－JPY
Other comprehensive income IFRSPrior1InterimDuration_OtherComponentsOfEquityIFRSMember－JPY
Other comprehensive income IFRSPrior1InterimDuration_EquityAttributableToOwnersOfParentIFRSMember－JPY
Other comprehensive income IFRSPrior1InterimDuration－JPY
Comprehensive income IFRSPrior1InterimDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSPrior1InterimDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSPrior1InterimDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSPrior1InterimDuration_RetainedEarningsIFRSMember-2122490000JPY
Comprehensive income IFRSPrior1InterimDuration_OtherComponentsOfEquityIFRSMember－JPY
Comprehensive income IFRSPrior1InterimDuration_EquityAttributableToOwnersOfParentIFRSMember-2122490000JPY
Comprehensive income IFRSPrior1InterimDuration-2122490000JPY
Purchase of treasury shares ss IFRSPrior1InterimDuration_ShareCapitalIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1InterimDuration_CapitalSurplusIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1InterimDuration_TreasurySharesIFRSMember-960908000JPY
Purchase of treasury shares ss IFRSPrior1InterimDuration_RetainedEarningsIFRSMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-12-31pass
balance sheet identityconsolidated 2026-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2026-01-01/2026-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2026-01-01/2026-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsconsolidated 2026-06-30pass